{
    "nct_id": "NCT04298606",
    "official_title": "A Phase 0 Study of CIMAvax-EGF Vaccine in Patients Who Are at High Risk for Lung Cancer and Lung Cancer Survivors at Risk for Recurrence",
    "inclusion_criteria": "* Confirmed no evidence of cancer on computed tomography (CT) scan within 6 months prior to starting treatment\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2\n* Patients must have platelets >= 100 x 10^9/L\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry\n\n  * Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure\n* PATIENTS AT HIGH-RISK FOR LUNG CANCER COHORT ONLY (COHORT A)\n* Must have documented at least one risk factor for lung cancer which includes:\n\n  * Moderate to severe chronic obstructive pulmonary disease (COPD) defined as FEV1/FVC ratio <=75%\n  * Positive family history of lung cancer defined as a first degree relative\n  * Low body mass index (BMI)\n  * History of pneumonia within the last 5 years prior to enrollment\n  * Occupational exposure such as asbestos, radon and any other that investigator would deem high risk\n* Must have quit smoking =< 15 years ago or be a current smoker\n* Must have at least 30 pack year smoking history\n* Must have documented pulmonary function test within the last 3 years prior to enrollment. If a patient cannot tolerate a pulmonary function test, an incentive spirometry will be acceptable in place of a pulmonary function test\n* LUNG CANCER SURVIVOR COHORT ONLY (COHORT B)\n* 1. If patient received surgery or any adjuvant therapy for initial diagnosis of lung cancer, it must have been completed at least 3 months prior to enrollment. Prior surgery or any therapy is not required for eligibility\n* Confirmed non-small cell lung cancer (NSCLC) stage IA through 3A at initial diagnosis\nHealthy volunteers allowed\nMust have minimum age of 50 Years\nMust have maximum age of 79 Years",
    "exclusion_criteria": "* Clinically inappropriate to have a bronchoscopy procedure\n* Known uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, history of clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant or nursing female participants\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug\n* Received an investigational agent within 30 days prior to enrollment\n* Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired immunodeficiency syndrome [AIDS] or other immune depressing disease). Testing is not mandatory\n* Patient has known hypersensitivity to the components of the study drugs or any analogs\n* History of autoimmune disorder, with exception of patients with vitiligo or endocrine-related autoimmune conditions receiving appropriate hormonal supplementation who are eligible. Systemic use of immunosuppressant drugs such as steroids (except as hormone replacement therapy or short-course supportive medication such as chemotherapy or drug allergy, etc.), azathioprine, tacrolimus, cyclosporine, etc. within 4 weeks before recruitment\n* The following special populations are excluded from this study:\n\n  * Cognitively impaired adults/adults with impaired decision-making capacity\n  * Individuals who are not yet adults (infants, children, teenagers)\n  * Prisoners\n  * Pregnant women",
    "miscellaneous_criteria": ""
}